VRAY - ViewRay, Inc.
| Previous Close | 3.1700 |
| Open | 3.1400 |
| Bid | 3.0500 x 2200 |
| Ask | 3.0600 x 1800 |
| Day's Range | 3.0100 - 3.1950 |
| 52 Week Range | 2.1200 - 9.7600 |
| Volume | 1,361,914 |
| Avg. Volume | 3,183,137 |
| Market Cap | 445.32M |
| Beta (5Y Monthly) | 1.27 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.0450 |
| Earnings Date | Nov 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.45 |
- PR Newswire
ViewRay Announces Preliminary Fourth Quarter and Full Year 2019 Results
ViewRay, Inc. (NASDAQ: VRAY) today announced preliminary results for the fourth quarter and full fiscal year ended December 31, 2019. The preliminary results have not been audited and are subject to change.
- Insider Monkey
Here is What Hedge Funds Think About ViewRay, Inc. (VRAY)
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Our research shows that most of the stocks that smart money likes historically generate strong […]
- PR Newswire
Michigan Community Hospital Begins Patient Treatments with ViewRay's MRIdian Linac
ViewRay, Inc. (Nasdaq: VRAY) announced today that Sparrow Health System in Lansing, Michigan has begun patient treatments with MRIdian® Linac, a cutting-edge radiation therapy system that combines the latest innovations in precision radiation delivery and ground-breaking MRI-guidance. The MRIdian device is located in the hospital's new Herbert-Herman Cancer Center, designed to deliver convenient and comprehensive patient care.
- PR Newswire
First MRIdian MRI-Guided Radiotherapy Treatments Begin in the United Kingdom
ViewRay, Inc. (Nasdaq: VRAY) announced today that the first MRIdian MRI-guided radiotherapy system in the United Kingdom (UK) – located at GenesisCare Oxford – has begun patient treatments. MRIdian combines high definition MRI imaging with linear accelerator radiation therapy to allow clinicians to visualize and adapt therapy as they treat tumors throughout the body.
- Simply Wall St.
Investors Who Bought ViewRay (NASDAQ:VRAY) Shares A Year Ago Are Now Down 33%
ViewRay, Inc. (NASDAQ:VRAY) shareholders will doubtless be very grateful to see the share price up 55% in the last...
- PR Newswire
ViewRay Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced the completion of its previously announced underwritten public offering of 47,782,500 shares of common stock at a price to the public of $3.13 per share, for gross proceeds of approximately $149.6 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ViewRay. All of the shares sold in the offering were sold by ViewRay. The shares sold included the full exercise of the underwriters' option to purchase additional shares.
- PR Newswire
ViewRay Announces Pricing of Public Offering of Common Stock
ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced the pricing of an underwritten public offering of 41,550,000 shares of common stock at a price to the public of $3.13 per share, for gross proceeds of approximately $130.1 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ViewRay. All of the shares to be sold in the offering will be offered by ViewRay. In addition, ViewRay has granted the underwriters of the offering a 30-day option to purchase up to an additional 6,232,500 shares of common stock at the public offering price, less underwriting discounts and commissions.
- Thomson Reuters StreetEvents
Edited Transcript of VRAY earnings conference call or presentation 12-Nov-19 9:30pm GMT
Q3 2019 ViewRay Inc Earnings Call
- Zacks
ViewRay Allies With Two Majors in MR-Guided Radiation Therapy
ViewRay's (VRAY) collective investments from Elekta and Medtronic are conditioned to the consummation of an equity capital hike of at least $75 million.
- PR Newswire
ViewRay Announces Proposed Public Offering of Common Stock
ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced that it has commenced an underwritten public offering of $75.0 million of shares of its common stock. In addition, ViewRay expects to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of shares of common stock at the public offering price, less the underwriting discounts and commissions. All of the shares of common stock to be sold in the offering will be offered by ViewRay. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
- PR Newswire
ViewRay Announces Collaborations with Elekta and Medtronic
ViewRay, Inc. (Nasdaq: VRAY) announced today that it has signed a non-binding memorandum of understanding for collaboration with Elekta AB (Nasdaq: EKTA-B.ST) ("Elekta") to advance the knowledge and use of MR-guided radiation therapy. In connection with the collaboration, Elekta has committed to invest capital for up to a 9.9% minority interest in ViewRay, subject to the terms and conditions set forth in a commitment agreement.
- Zacks
Options Traders Expect Huge Moves in ViewRay (VRAY) Stock
Investors need to pay close attention to ViewRay (VRAY) stock based on the movements in the options market lately.
- PR Newswire
ViewRay® to Present at the 2019 Piper Jaffray 31st Annual Healthcare Conference
CLEVELAND , Nov. 20, 2019 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the Company will participate in the 2019 Piper Jaffray 31 st Annual Healthcare Conference in New York, New York ...
- GlobeNewswire
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Meredith Corporation, McKesson Corporation, Maxar Technologies, and ViewRay and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, is investigating certain officers and directors of Meredith Corporation (MDP), McKesson Corporation (MCK), Maxar Technologies, Inc. (MAXR), and ViewRay, Inc. (VRAY) on behalf of long-term stockholders. Bragar Eagel & Squire is investigating certain officers and directors of Meredith Corporation following a class action complaint that was filed against Meredith Corporation on September 6, 2019.
- ACCESSWIRE
SHAREHOLDER ALERT: SEE VRAY TEUM: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, NY / ACCESSWIRE / November 12, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered ...
- Zacks
ViewRay (VRAY) Reports Q3 Loss, Tops Revenue Estimates
ViewRay (VRAY) delivered earnings and revenue surprises of 22.22% and 0.35%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
ViewRay Reports Third Quarter 2019 Results
CLEVELAND , Nov. 12, 2019 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the third quarter ended September 30, 2019. Third Quarter 2019 Summary: Total revenue was $20.9 ...
- ACCESSWIRE
FINAL DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against ViewRay, Inc. and Encourages Investors with Losses in Excess of $50,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / November 12, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against ViewRay, Inc. ("ViewRay" or "the Company") (NASDAQ:VRAY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between March 15, 2019 and August 8, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before November 12, 2019.
- ACCESSWIRE
CLASS ACTION UPDATE for VRAY, WTRH and SDC: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / November 12, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine ...
- Business Wire
TUESDAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against ViewRay, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ViewRay, Inc. (“ViewRay” or “the Company”) (NASDAQ: VRAY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- GlobeNewswire
CLASS ACTION UPDATE for VRAY, SDC, TEUM and QUAD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. Allegations: Viewray, Inc. made materially false and/or misleading statements and/or failed to disclose that: (a) demand for ViewRay systems had declined due in part to changes being made to Medicare reimbursement approaches first announced in November 2019 that could make purchases of new ViewRay systems less profitable for customers; (b) the Company’s reported backlog was overstated due to the inclusion of orders with insufficient surety as to permit for their inclusion in reported backlog; and (c) as a result of the foregoing, defendants’ positive statements about ViewRay’s business metrics and financial prospects during the Class Period were materially false and misleading and/or lacked a reasonable basis.
- PR Newswire
INVESTOR ALERT - ViewRay, Inc. (VRAY) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Deadline: November 12, 2019
NEW YORK, Nov. 12, 2019 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against ViewRay, Inc. ("ViewRay" or "the Company") (NASDAQ: VRAY) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired ViewRay securities between March 15, 2019 and August 8, 2019, both dates inclusive. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) demand for ViewRay systems had declined due in part to changes being made to Medicare reimbursement approaches first announced in November 2018 that could make purchases of new ViewRay systems less profitable for customers; (2) the Company's reported backlog was overstated due to the inclusion of orders with insufficient surety as to permit for their inclusion in reported backlog; and (3) as a result, ViewRay's public statements were materially false and misleading at all relevant times.
- ACCESSWIRE
VRAY DEADLINE TODAY: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts ViewRay (VRAY) Investors of Today’s Deadline to Move for Lead Plaintiff
SAN FRANCISCO, CA / ACCESSWIRE / November 12, 2019 / Hagens Berman alerts ViewRay, Inc. (NASDAQ:VRAY) investors of today's lead plaintiff deadline to move for lead plaintiff in a federal securities class ...
- GlobeNewswire
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of VRAY and OLLI of Upcoming Deadlines
WILMINGTON, Del., Nov. 11, 2019 -- Rigrodsky & Long, P.A. reminds investors of upcoming deadlines involving securities fraud class action lawsuits commenced against the.
- GlobeNewswire
VIEWRAY 24 HOUR DEADLINE ALERT: FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Deadline in Class Action Lawsuit Against ViewRay, Inc. - VRAY
NEW ORLEANS, Nov. 11, 2019 -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they.
